Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2010 Nov 13;24(17):2679-86.
doi: 10.1097/QAD.0b013e32833f6294.

Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study

Michael T Yin  1 , Qiuhu Shi, Donald R Hoover, Kathryn Anastos, Anjali Sharma, Mary Young, Alexandra Levine, Mardge H Cohen, Elizabeth Shane, Elizabeth T Golub, Phyllis C Tien
Affiliations
Multicenter Study

Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study

Michael T Yin et al. AIDS. .

Abstract

Background: The clinical importance of the association of HIV infection and antiretroviral therapy (ART) with low bone mineral density (BMD) in premenopausal women is uncertain because BMD stabilizes on established ART and fracture data are limited.

Methods: We measured time to first new fracture at any site with median follow-up of 5.4 years in 2391 (1728 HIV-infected, 663 HIV-uninfected) participants in the Women's Interagency HIV Study (WIHS). Self-report of fracture was recorded at semiannual visits. Proportional hazard models assessed predictors of incident fracture.

Results: At baseline, HIV-infected women were older (40 ± 9 vs. 36 ± 10 years, P < 0.0001), more likely to report postmenopausal status and be hepatitis C virus-infected, and weighed less than HIV-uninfected women. Among HIV-infected women, mean CD4(+) cell count was 482 cells/μl; 66% were taking ART. Unadjusted incidence of fracture did not differ between HIV-infected and uninfected women (1.8 vs. 1.4/100 person-years, respectively, P = 0.18). In multivariate models, white (vs. African-American) race, hepatitis C virus infection, and higher serum creatinine, but not HIV serostatus, were statistically significant predictors of incident fracture. Among HIV-infected women, older age, white race, current cigarette use, and history of AIDS-defining illness were associated with incidence of new fracture.

Conclusion: Among predominantly premenopausal women, there was little difference in fracture incidence rates by HIV status, rather traditional risk factors were important predictors. Further research is necessary to characterize fracture risk in HIV-infected women during and after the menopausal transition.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
(a) Incidence of new fracture (fragility or nonfragility) at any site, unadjusted in HIV-infected (dashed line) and uninfected (solid line) women (P = 0.13). (b). Incidence of new fracture (fragility or nonfragility) at any site adjusted for age, race, hepatitis C virus infection, and serum creatinine in HIV-infected (dashed line) and uninfected (solid line) women (P = 0.54).
See this image and copyright information in PMC

References

    1. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20:2165–2174. - PubMed
    1. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009;51:554–561. - PubMed
    1. Cassetti I, Madruga JV, Suleiman JM, Etzel A, Zhong L, Cheng AK, Enejosa J. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials. 2007;8:164–172. - PubMed
    1. Duviver C, Kolta S, Assoumou L, Gohosn J, Rozenberg S, Murphy R, et al. First-line PI-containing regimens enhance decreased bone mineral density greater than NNRTI-containing regimen in HIV-1 infected patients: A substudy of the HIPPOCAMPE-ANRS 121 Trial. 15th Conference on Retroviruses and Opportunistic Infections; Boston, MA. 2008.
    1. Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 2009;23:1519–1529. - PMC - PubMed

Publication types